Maria-Cruz Morillo | Global Therapeutic Operations Lead, Rare Diseases
Allucent
Maria-Cruz Morillo, MS Pharmacy, has a strong background in drug development with 29 years of experience in project management and strategy and IMP supply in both biotech and CROs. Her strategic mindset and demonstrated ability to design and implement effective study protocols has contributed significantly to the achievement of market authorizations for numerous rare endocrinology and hematology autoimmune programs. In her current role at Allucent, Maria-Cruz is head of the company's global team of rare disease experts, integrating their cross functional expertise to provide strategic solutions that foster successful outcomes in rare disease clinical trials and ensure excellence in delivery.
Appearances:
Day 2 - Wednesday 29 October @ 11:15
Endpoint Adjudication in Rare Disease Trials: Navigating Uncertainty and Advancing Objectivity in Outcome Assessment
Sources of uncertainty in rare disease endpoints and strategies to address them.
Standardizing endpoint definitions and assessment criteria.
Use of blinded independent adjudication committees.
Practical steps for implementing effective adjudication processes.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events